Findings

What do systematic reviews say?

4,678 questions · 4,859 findings · 283 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Summary of findings ‐ Exercise A vs Exercise B

Adverse events · participants with haemophilia

The review found no eligible studies for this question.

1 finding from 1 review

Exercise for haemophilia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ Exercise A vs Exercise B

Quality of life · participants with haemophilia

The review found no eligible studies for this question.

1 finding from 1 review

Exercise for haemophilia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Defibrotide vs no treatment

Incidence of hepatic veno‐occlusive disease ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease

Summary of findings: Defibrotide showed no clear difference in incidence of hepatic veno‐occlusive disease ( compared with no treatment (low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
RR 0.62 [0.38, 1.02]
1 study · 360 participants
Low

Summary of findings: Defibrotide vs no treatment

Overall survival ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease

Summary of findings: Defibrotide showed no clear difference in overall survival ( compared with no treatment (low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
HR 1.04 [0.54, 2.02]
1 study · 356 participants
Low

Summary of findings: Defibrotide vs no treatment

All‐cause mortality at 100 days post‐transplant · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease

Summary of findings: Defibrotide showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
RR 1.05 [0.56, 1.97]
1 study · 360 participants
Low

Summary of findings: Defibrotide vs no treatment

Mortality attributable to hepatic veno‐occlusive disease ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease

Summary of findings: Defibrotide showed no clear difference in mortality attributable to hepatic veno‐occlusive disease ( compared with no treatment (low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
RR 0.4 [0.13, 1.24]
1 study · 360 participants
Low

Summary of findings: Defibrotide vs no treatment

Quality of life · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Defibrotide vs no treatment

Frequency of adverse events ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease

It is very uncertain whether summary of findings: Defibrotide changes frequency of adverse events ( compared with no treatment (very low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
RR 18.79 [1.1, 320.45]
1 study · 360 participants
Very low

Antibiotics vs placebo or no intervention

All cause mortality · patients with afebrile neutropenia induced by chemotherapy

Summary of findings: antibiotics leads to lower all cause mortality compared with placebo or no intervention (high certainty).

1 finding from 1 review

Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy 2012 · Cochrane Headline outcomes only
RR 0.66
46 studies · 5635 participants
High

Antibiotics vs placebo or no intervention

Febrile patients and episodes · patients with afebrile neutropenia induced by chemotherapy

Summary of findings: antibiotics probably leads to lower febrile patients and episodes compared with placebo or no intervention (moderate certainty).

1 finding from 1 review

Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy 2012 · Cochrane Headline outcomes only
RR 0.8
54 studies · 6658 participants
Moderate

Antibiotics vs placebo or no intervention

Bacteraemia · patients with afebrile neutropenia induced by chemotherapy

Summary of findings: antibiotics leads to lower bacteraemia compared with placebo or no intervention (high certainty).

1 finding from 1 review

Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy 2012 · Cochrane Headline outcomes only
RR 0.5
53 studies · 6390 participants
High

Leflunomide vs placebo, 6 months

For outcome · patients with rheumatoid arthritis in adults

The review found no eligible studies for this question.

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leflunomide vs placebo, 6 months

ACR 50 response at 6 months · patients with rheumatoid arthritis in adults

Summary of findings: leflunomide leads to higher ACR 50 response at 6 months compared with placebo, 6 months (high certainty).

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
RR 2.32 [1.32, 4.05]
1 study · 221 participants
High

Leflunomide vs placebo, 6 months

HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 679 participants
High

Leflunomide vs placebo, 6 months

Pain change (0‐100 mm VAS) · patients with rheumatoid arthritis in adults

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 724 participants
High

Leflunomide vs placebo, 6 months

Radiographic joint changes · patients with rheumatoid arthritis in adults

Summary of findings: leflunomide showed no clear difference in radiographic change (Change in Sharp score) compared with placebo, 6 months (high certainty).

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
RR 1.23 [0.91, 1.66]
1 study · 380 participants
High

Leflunomide vs placebo, 6 months

Withdrawals due to adverse events · patients with rheumatoid arthritis in adults

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 727 participants
High

Hydroxyurea vs placebo

Pain alterationa · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 784 participants
Moderate

Hydroxyurea vs observation

Pain alteration · adults and children with sickle cell disease and an increased risk of stroke

The review found no eligible studies for this question.

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs observation

Life‐threatening illness · adults and children with sickle cell disease and an increased risk of stroke

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low